Cargando…

Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination

Hypertension affects nearly one-third of all individuals in the US, yet one-half of all treated patients achieve blood pressure (BP) controlled to recommended goals. The percentage of patients with uncontrolled BP is likely to be much higher when considering the number of patients who are not even a...

Descripción completa

Detalles Bibliográficos
Autor principal: Punzi, Henry A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3257873/
https://www.ncbi.nlm.nih.gov/pubmed/22253546
http://dx.doi.org/10.2147/IBPC.S12214
_version_ 1782221213409476608
author Punzi, Henry A
author_facet Punzi, Henry A
author_sort Punzi, Henry A
collection PubMed
description Hypertension affects nearly one-third of all individuals in the US, yet one-half of all treated patients achieve blood pressure (BP) controlled to recommended goals. The percentage of patients with uncontrolled BP is likely to be much higher when considering the number of patients who are not even aware of their hypertensive state. Elevated BP is associated with increased risks of cardiovascular events and end-organ damage. Antihypertensive monotherapy is not always sufficient to achieve BP goals, and thus more aggressive treatment regimens need to be considered. Antihypertensive combination therapy, which may improve tolerability, offers the benefit of targeting different mechanisms of action. Numerous outcomes studies support the use of a renin–angiotensin system inhibitor as a first-line choice in antihypertensive therapy. This review discusses the benefits of combination therapy with the angiotensin type II receptor blocker olmesartan medoxomil (OM) paired with the thiazide diuretic hydrochlorothiazide (HCTZ). The pharmacokinetic properties of OM will be reviewed in addition to efficacy studies that support OM + HCTZ combination therapy over other possible antihypertensive combinations. Finally, a rationale for choosing HCTZ over another diuretic, chlorthalidone, will also be discussed based on pharmacokinetic differences, clinical concerns, and trends in use.
format Online
Article
Text
id pubmed-3257873
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-32578732012-01-17 Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination Punzi, Henry A Integr Blood Press Control Review Hypertension affects nearly one-third of all individuals in the US, yet one-half of all treated patients achieve blood pressure (BP) controlled to recommended goals. The percentage of patients with uncontrolled BP is likely to be much higher when considering the number of patients who are not even aware of their hypertensive state. Elevated BP is associated with increased risks of cardiovascular events and end-organ damage. Antihypertensive monotherapy is not always sufficient to achieve BP goals, and thus more aggressive treatment regimens need to be considered. Antihypertensive combination therapy, which may improve tolerability, offers the benefit of targeting different mechanisms of action. Numerous outcomes studies support the use of a renin–angiotensin system inhibitor as a first-line choice in antihypertensive therapy. This review discusses the benefits of combination therapy with the angiotensin type II receptor blocker olmesartan medoxomil (OM) paired with the thiazide diuretic hydrochlorothiazide (HCTZ). The pharmacokinetic properties of OM will be reviewed in addition to efficacy studies that support OM + HCTZ combination therapy over other possible antihypertensive combinations. Finally, a rationale for choosing HCTZ over another diuretic, chlorthalidone, will also be discussed based on pharmacokinetic differences, clinical concerns, and trends in use. Dove Medical Press 2011-12-07 /pmc/articles/PMC3257873/ /pubmed/22253546 http://dx.doi.org/10.2147/IBPC.S12214 Text en © 2011 Punzi, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Punzi, Henry A
Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination
title Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination
title_full Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination
title_fullStr Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination
title_full_unstemmed Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination
title_short Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination
title_sort integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3257873/
https://www.ncbi.nlm.nih.gov/pubmed/22253546
http://dx.doi.org/10.2147/IBPC.S12214
work_keys_str_mv AT punzihenrya integratedcontrolofhypertensionbyolmesartanmedoxomilandhydrochlorothiazideandrationaleforcombination